Table 2.
Relative risks and 95% confidence intervals (CI) of total breast cancer by quintiles of plasma measures
| Quintile of plasma measure | P for Trend | |||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | ||
| Folate, ng/mL | <10.2 | 10.2 to 13.8 | 13.9 to 17.9 | 18.0 to 23.6 | ≥23.7 | |
| Cases/Controls | 109/240 | 103/242 | 143/240 | 125/241 | 129/240 | |
| Simple relative risk* (95% Cl) | 1.00 (ref.) | 0.96 (0.68, 1.35) | 1.24 (0.90, 1.72) | 1.12 (0.81, 1.56) | 1.25 (0.90, 1.74) | 0.13 |
| Multivariable relative risk† (95% Cl) | 1.00 (ref.) | 0.99 (0.70, 1.40) | 1.20 (0.86, 1.67) | 1.11 (0.79, 1.55) | 1.18(0.84, 1.66) | 0.28 |
| Vitamin B12, pg/mL | <281 | 281 to 371 | 372 to 472 | 473 to 619 | ≥620 | |
| Cases/Controls | 93/240 | 124/241 | 123/241 | 118/241 | 150/241 | |
| Simple relative risk* (95% Cl) | 1.00 (ref.) | 1.42(1.02, 1.98) | 1.53 (1.09, 2.14) | 1.40(1.00, 1.96) | 1.71 (1.23, 2.37) | 0.008 |
| Multivariable relative risk† (95% Cl) | 1.00 (ref.) | 1.42(1.01, 2.01) | 1.57(1.11, 2.21) | 1.42(1.01, 2.00) | 1.64(1.17, 2.29) | 0.02 |
| Pyridoxal 5’-phosphate, pmol/mL | <30.0 | 30.0 to 41.8 | 41.9 to 58.6 | 58.7 to 96.1 | ≥96.2 | |
| Cases/Controls | 112/241 | 123/242 | 120/241 | 122/242 | 133/241 | |
| Simple relative risk* (95% Cl) | 1.00 (ref.) | 1.15 (0.83, 1.58) | 1.13 (0.82, 1.57) | 1.16(0.84, 1.61) | 1.30(0.95, 1.79) | 0.14 |
| Multivariable relative risk† (95% Cl) | 1.00 (ref.) | 1.13 (0.82, 1.58) | 1.02 (0.73, 1.42) | 1.06 (0.75, 1.48) | 1.18(0.85, 1.64) | 0.4 |
| Homocysteine, nmol/mL | <7.5 | 7.5 to 8.6 | 8.7 to 9.7 | 9.8 to 11.3 | ≥11.4 | |
| Cases/Controls | 128/239 | 121/241 | 109/239 | 124/240 | 127/240 | |
| Simple relative risk* (95% Cl) | 1.00 (ref.) | 0.90 (0.65, 1.24) | 0.82 (0.59, 1.13) | 0.90 (0.65, 1.23) | 0.93 (0.68, 1.28) | 0.81 |
| Multivariable relative risk† (95% Cl) | 1.00 (ref.) | 0.88 (0.64, 1.22) | 0.80 (0.57, 1.11) | 0.90 (0.65, 1.24) | 0.93 (0.67, 1.28) | 0.85 |
| Cysteine, nmol/mL | <218.0 | 218.0 to 235.7 | 235.8 to 249.9 | 250.0 to 268.1 | ≥268.2 | |
| Cases/Controls | 99/241 | 125/241 | 125/242 | 138/241 | 121/241 | |
| Simple relative risk* (95% Cl) | 1.00 (ref.) | 1.15 (0.83, 1.60) | 1.15 (0.83, 1.61) | 1.22 (0.88, 1.69) | 1.16(0.83, 1.62) | 0.42 |
| Multivariable relative risk† (95% Cl) | 1.00 (ref.) | 1.11 (0.79, 1.56) | 1.13 (0.80, 1.58) | 1.18 (0.84, 1.65) | 1.14(0.81, 1.62) | 0.46 |
| Cysteinylglycine, nmol/mL | <200.0 | 200.0 to 229.7 | 229.8 to 260.6 | 260.7 to 304.6 | ≥304.7 | |
| Cases/Controls | 111/239 | 123/240 | 131/240 | 134/240 | 102/240 | |
| Simple relative risk* (95% Cl) | 1.00 (ref.) | 1.04 (0.75, 1.44) | 1.13 (0.82, 1.56) | 1.12 (0.81, 1.55) | 0.87 (0.62, 1.22) | 0.46 |
| Multivariable relative risk† (95% Cl) | 1.00 (ref.) | 1.04 (0.75, 1.45) | 1.12 (0.81, 1.56) | 1.09 (0.79, 1.52) | 0.93 (0.66, 1.31) | 0.69 |
*
Unconditional logistic regression with adjustments for matching factors.
†
Unconditional logistic regression with the adjustments for matching factors, age at menarche, parity/age at first birth, history of breast cancer in mother or a sister, history of benign breast disease, height, body mass index at age 18, weight change since 18, and alcohol intake.